488 GNUV201, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer immunotherapy

Abstract

BackgroundSeveral PD-1 antibodies have been approved as anti-cancer therapies which work by blocking the interaction of PD-1 with its ligand PD-L1, thus restoring anti-cancer T cell activities. However, cross-reactive anti-PD-1...